摘要
CAR T(chimeric antigen receptor T-cell)therapy represents a paradigm shift in cancer treatments.By empowering immune cells to target malignant cells directly,it opens another door to precision medicine,promising cures for once refractory malignancies.However,the extension of CAR T therapy to solid tumors confronts formidable obstacles1.The physical and biochemical barriers within the tumor microenvironment,such as dense extracellular matrices and immunosuppressive factors,impede CAR T cell infiltration and function,leading to diminished success rates in solid tumor treatment2.
